Dermatology News and Research RSS Feed - Dermatology News and Research

Dermatology is the branch of medicine dealing with the skin and its diseases. Dermatologists take care of diseases and cancers of the skin, scalp, hair, and nails.
European chestnut leaves contain ingredients with power to disarm deadly staph bacteria

European chestnut leaves contain ingredients with power to disarm deadly staph bacteria

Leaves of the European chestnut tree contain ingredients with the power to disarm dangerous staph bacteria without boosting its drug resistance, scientists have found. [More]
Nuvo Research granted U.S. patent for novel topical foam formulations that use DMSO to enhance drug delivery

Nuvo Research granted U.S. patent for novel topical foam formulations that use DMSO to enhance drug delivery

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that the United States Patent Office has granted U.S. patent no. 9,107,823 ('823 Patent) covering novel topical foam formulations that include dimethyl sulfoxide (DMSO) together with certain drug actives. [More]
Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones. [More]
Mesenchymal stem cell exosomes offer hope in healing chronic wounds

Mesenchymal stem cell exosomes offer hope in healing chronic wounds

Dr. Badiavas’ research demonstrates how mesenchymal stem cell (MSC) exosomes, cell-derived vesicles that exist in biological fluids, function to repair non-healing wounds. [More]
Early exposure to inflammatory cytokines can paralyze CD4 T cells

Early exposure to inflammatory cytokines can paralyze CD4 T cells

In a discovery that is likely to rewrite immunology text books, researchers at UC Davis have found that early exposure to inflammatory cytokines, such as interleukin 2, can "paralyze" CD4 T cells, immune components that help orchestrate the body's response to pathogens and other invaders. [More]
Astellas Farma Brasil named one of Top 20 places to work in Brazil

Astellas Farma Brasil named one of Top 20 places to work in Brazil

Astellas Farma Brasil is one of the Top 20 small- to medium-sized companies to work for in the country across all industries, according to the Great Place to Work Institute's latest rankings. The results are based on a survey of thousands of employees across multiple industries in Brazil. [More]
Organ transplant recipients more likely to develop melanoma

Organ transplant recipients more likely to develop melanoma

Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant, and three times more likely to die of the dangerous skin cancer, suggests new research led by a Johns Hopkins Bloomberg School of Public Health student. [More]
Novel combination therapy effective at treating patients with skin metastases

Novel combination therapy effective at treating patients with skin metastases

In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown. [More]
Endra photoacoustic CT preclinical imaging technology to be brought to Australia by AXT

Endra photoacoustic CT preclinical imaging technology to be brought to Australia by AXT

AXT is proud to announce that they have just signed an exclusive distributorship agreement with US-based Endra Life Sciences. Endra are a developer of photoacoustic (PA) technology for bio-medical imaging and have commercialised their breakthrough technology. This new deal further bolsters AXT’s life science and preclinical imaging portfolios with another unique technology. [More]
Novel treatment target found for RV failure in PAH

Novel treatment target found for RV failure in PAH

Researchers have identified a molecular pathway by which downregulation of microRNA-126 contributes to right ventricular failure in patients with pulmonary arterial hypertension. [More]
Low GLSRV heralds adverse outcomes in PAH patients

Low GLSRV heralds adverse outcomes in PAH patients

Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators. [More]
Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) - a rare type of non-Hodgkin lymphoma that affects the skin. [More]
Pennsylvania physicians examine back-to-school health, offer tips for parents and students

Pennsylvania physicians examine back-to-school health, offer tips for parents and students

As students start heading back to classes for the upcoming academic year, Pennsylvania physicians take a close look at back-to-school health and offer some tips for parents and students who strive to stay in class and not home in bed sick. [More]
Results of IPC survey identifying 21 psoriasis research priorities published in British Journal of Dermatology

Results of IPC survey identifying 21 psoriasis research priorities published in British Journal of Dermatology

The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal. [More]
Penn researchers identify major genetic factor that keeps moles in non-cancerous, no-growth state

Penn researchers identify major genetic factor that keeps moles in non-cancerous, no-growth state

Moles are benign tumors found on the skin of almost every adult. Scientists have known for years that a mutation in the BRAF gene makes them start growing, but until now haven't understood why they stop. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania have identified a major genetic factor that keeps moles in their usual non-cancerous, no-growth state. [More]
Cipher receives Acceptance Review Notification from FDA for 510(k) submission for Dermadexin

Cipher receives Acceptance Review Notification from FDA for 510(k) submission for Dermadexin

Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration. [More]
Soldiers returning from combat missions in Iraq and Afghanistan at increased risk of skin cancer

Soldiers returning from combat missions in Iraq and Afghanistan at increased risk of skin cancer

Soldiers who served in the glaring desert sunlight of Iraq and Afghanistan returned home with an increased risk of skin cancer, due not only to the desert climate, but also a lack of sun protection, Vanderbilt dermatologist Jennifer Powers, M.D., reports in a study published recently in the Journal of Investigative Dermatology. [More]
Intracellular microlasers may allow accurate measurement of small changes occurring within cells

Intracellular microlasers may allow accurate measurement of small changes occurring within cells

Massachusetts General Hospital (MGH) investigators have induced structures incorporated within individual cells to produce laser light. [More]
One sunburn increases risk of skin cancer by 50%

One sunburn increases risk of skin cancer by 50%

Everybody's got a story about that "one bad burn" - the time you fell asleep next to the pool and tattooed a white handprint on your lobster-red chest, or forgot to pack the sunscreen while hiking a Colorado 14er. [More]

RepliCel Life Sciences announces final design specifications for next-generation dermal injector

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company, is pleased to announce that the final design specifications of its next-generation dermal injector (RCI-02) have been locked. Prototypes for industrial and regulatory testing will now be built to prepare for an application for CE mark clearance to market the injector in Europe in 2016. [More]
Advertisement